---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285762418.md"
description: "Definium Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results. Also, Piper Sandler lowered its price target on the stock from $49 to $48."
datetime: "2026-05-08T17:51:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285762418.md)
  - [en](https://longbridge.com/en/news/285762418.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285762418.md)
---

# 

Definium Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results. Also, Piper Sandler lowered its price target on the stock from $49 to $48.

### Related Stocks

- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)

## Related News & Research

- [Watch live: Rethinking Psychedelic Treatment for America's Mental Health Crisis](https://longbridge.com/en/news/286901819.md)
- [Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 311% One Year Surge?](https://longbridge.com/en/news/283707382.md)
- [IBM Stock Leads Mega-Cap Stock Decliners as Market Volatility Triggers Steep Selloff. That Doesn’t Tell You the Whole Story.](https://longbridge.com/en/news/286966714.md)
- [Definium Therapeutics (DFTX): Late-Stage DT120 Psychedelic Pipeline and Multiple Near-Term Catalysts Support Buy Rating and $61 Target](https://longbridge.com/en/news/284048357.md)
- [Definium Therapeutics (NASDAQ:DFTX) Issues Earnings Results](https://longbridge.com/en/news/285796112.md)